Dyslipidemia News and Research RSS Feed - Dyslipidemia News and Research

Dyslipidemia is a disruption in the amount of lipids in the blood.
Rates of stroke incidence, subsequent death decrease among black and white U.S. adults

Rates of stroke incidence, subsequent death decrease among black and white U.S. adults

In a study that included a large sample of black and white U.S. adults from several communities, rates of stroke incidence and subsequent death decreased from 1987 to 2011, with decreases varying across age-groups, according to a study in the July 16 issue of JAMA. [More]
Study reveals mechanism underlying abnormal fat accumulation in HIV patients

Study reveals mechanism underlying abnormal fat accumulation in HIV patients

Building upon their earlier research on the biology of fat metabolism, Joslin scientists discovered that microRNAs -small RNA molecules that play important roles in regulation in many types of tissue - play a major role in the distribution and determination of fat cells and whole body metabolism. [More]
Study calls for more proactive approach towards complete dyslipidemia diagnosis in clinical practice

Study calls for more proactive approach towards complete dyslipidemia diagnosis in clinical practice

Clinical inertia does not allow healthcare professionals to diagnose cholesterol problems in the 65.3% of cases. The results warn of the need to adopt a more proactive attitude towards a complete dyslipidemia diagnosis in routine clinical practice, especially if it is taken into account that it is an illness related to an increase of cardiovascular risk. [More]
Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. [More]
Weight loss most important factor for improving cardiovascular health in obese OSA patients

Weight loss most important factor for improving cardiovascular health in obese OSA patients

Obesity and obstructive sleep apnea (OSA) tend to co-exist and are associated with a variety of cardiovascular risk factors, including inflammation, insulin resistance, abnormal cholesterol, and high blood pressure. While effective therapies are available for OSA, researchers are still unclear about what interventions are most effective in reducing the burden of risk factors for cardiovascular disease associated with OSA in obese patients. [More]
Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

The International Society for Autism Research (INSAR), a scientific and professional organization devoted to advancing knowledge about autism spectrum disorders, convened more than 1700 researchers, delegates, autism specialists and students from 40 countries for the 13th Annual International Meeting for Autism Research (IMFAR), the world's largest scientific gathering on autism research, from May 15 through May 17 at the Atlanta Marriott Marquis in Atlanta, GA. [More]
Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates. [More]
AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL). [More]
Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Metabolic disorders are alterations in metabolic processes that can cause harm to a subject. The most common disorders affect the glucose and lipid metabolism causing diabetes and dyslipidemia. Another common disorder is obesity that affects many distinct metabolic processes. [More]
Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society. [More]
Measurement of calcium in coronary arteries can predict heart disease risk

Measurement of calcium in coronary arteries can predict heart disease risk

With growing evidence that a measurement of the buildup of calcium in coronary arteries can predict heart disease risk, Los Angeles Biomedical Research Institute (LA BioMed) researchers found that the process of "calcium scoring" was also accurate in predicting the chances of dying of heart disease among adults with little or no known risk of heart disease. [More]
Mayo Clinic research shows RA patients more likely to develop chronic kidney disease

Mayo Clinic research shows RA patients more likely to develop chronic kidney disease

Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows. [More]
Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Two new studies presented today at the International Liver CongressTM 2014 have provided more evidence to clarify the role of non-alcoholic fatty liver disease (NAFLD) as an independent risk factor for the development of cardiovascular disease (CVD). [More]
Research shows that rheumatoid arthritis patients are at higher risk of kidney disease

Research shows that rheumatoid arthritis patients are at higher risk of kidney disease

Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows. [More]
Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol. [More]
Research roundup: Distance from a transplant center; Medicaid prenatal care; metastasis of email; profiting from Medicare Advantage

Research roundup: Distance from a transplant center; Medicaid prenatal care; metastasis of email; profiting from Medicare Advantage

Centralization of specialized health care services such as organ transplantation and bariatric surgery is advocated to improve quality, increase efficiency, and reduce cost. [More]
Findings underscore importance of universal pediatric cholesterol screening

Findings underscore importance of universal pediatric cholesterol screening

Roughly one out of three kids screened for high cholesterol between the ages of 9 and 11 has borderline or high cholesterol, potentially placing them at greater risk for future cardiovascular disease, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
High-quality early childhood development programs can help prevent onset of adult chronic disease

High-quality early childhood development programs can help prevent onset of adult chronic disease

High-quality early childhood development programs with health care and nutritional components can help prevent or delay the onset of adult chronic disease, according to a new study by Nobel laureate economist James Heckman and researchers at the University of Chicago, University College London and the Frank Porter Graham Child Development Institute at the University of North Carolina. [More]
New data shows curative effects of GFT505 in NASH associated with metabolic disorders

New data shows curative effects of GFT505 in NASH associated with metabolic disorders

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new data from Professor Isabelle Leclercq of Université Catholique de Louvain (Belgium) demonstrating the curative effects of GFT505 in an experimental model of NASH associated with metabolic disorders. [More]
Patients with metabolic syndrome are more likely to have complications after total joint replacement

Patients with metabolic syndrome are more likely to have complications after total joint replacement

In a new study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), researchers found that total joint replacement patients with three or more metabolic syndrome risk factors were almost three times as likely to have complications within the first year after joint replacement. [More]